On January 11, 2022 Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, reported a pipeline milestone update on its TriTAC development programs (Press release, Harpoon Therapeutics, JAN 11, 2022, View Source [SID1234598592]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to begin 2022 with a catalyst rich year that will be driven by our multiple TriTAC clinical programs, including advancing our HPN217 program into the next phase of development," stated Julie Eastland, President and CEO, Harpoon Therapeutics. "We also expect to submit our first IND for HPN601, targeting EpCAM, from our ProTriTAC technology platform as well as advance an additional preclinical candidate into IND enabling studies as we continue to build out our future clinical pipeline."

Anticipated 2022 Milestones

TriTAC Clinical Programs

HPN328 – Continue dose escalation to determine RP2D by year-end 2022

HPN217 – Select the RP2D and initiate dose expansion cohort during the first half of 2022

HPN536 – Complete dose escalation by year-end 2022

HPN424 – Complete dose escalation during the second half of 2022
Platform Technologies and Next Clinical Candidate

HPN601 – IND submission by year-end 2022

Platform technologies – Advance a clinical candidate into IND enabling studies during the second half of 2022
Corporate Update Events

Harpoon will host an R&D Day during the first half of 2022